Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542773 · ClinicalTrials.gov registry record · Phase 1
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
A Phase 1 study of Schwannomas and Malignant Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT03542773: Completed Phase 1 study of Schwannomas and Malignant Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT03542773 is a Phase 1 study of Schwannomas and Malignant Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03542773, a Phase 1 study of Schwannomas and Malignant Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
Conditions Studied
Interventions
- DRUG 18F-DCFPyL Injection
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-02-06 |
| Est. Completion | 2022-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542773
The ClinicalTrials.gov registry entry for NCT03542773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schwannomas appearing as the primary indexed condition, and to 1 intervention - of which 18F-DCFPyL Injection is the first listed.
NCT03542773 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03542773 about?
NCT03542773 is a clinical study titled "Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET". To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
What is the current status of trial NCT03542773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2015-02-06. Estimated completion is 2022-05-01.
What conditions does trial NCT03542773 study?
This clinical trial studies the following conditions: Schwannomas, Malignant Tumors.
What interventions are being tested in trial NCT03542773?
The interventions under investigation include: 18F-DCFPyL Injection (DRUG).
Who is sponsoring clinical trial NCT03542773?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03542773 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schwannomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001214 · 38 participants
Collection of Blood From Patients With Pancytopenia
- NCT00001546 · 38 participants
Circadian Regulation of Sleep in Habitual Short Sleepers and Long Sleepers
- NCT00001899 · 38 participants
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
- NCT00055068 · 38 participants · Phase 3
Family Based Treatment of Early Childhood Obsessive Compulsive Disorder
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.